S*Bio Develops Singapore's First Clinical Anti-Cancer Drug Candidate
Novel HDAC inhibitor SB939
S*BIO anticipates that clinical trials of SB939 will commence both in Singapore and in North America in Q1 2007. In preclinical studies, SB939 demonstrates excellent anti-cancer efficacy. SB939 has the potential to be used as an oral therapy for a variety of human haematological malignancies and solid tumours. SB939 belongs to a novel series of targeted small molecule based anti-cancer agents that inhibit histone deacetylases (HDAC), enzymes that are important regulators of pro-apoptotic factors and proteins involved in cell cycle progression and differentiation.
"We are very excited about the success of SB939 and are strongly committed to accelerating its clinical development," commented Dr. Jan-Anders Karlsson, Chief Executive Officer of S*BIO. Moving forward, S*BIO will drive other programs, including next generation HDAC inhibitors and a new type of kinase inhibitors, which are targeted to reach preclinical development by the end of 2006.
Most read news
Topics
Organizations
Other news from the department manufacturing
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.